Evaluation of a 6-Year Highly Active Antiretroviral Therapy in Chinese HIV-1-Infected Patients

@article{Zhou2010EvaluationOA,
  title={Evaluation of a 6-Year Highly Active Antiretroviral Therapy in Chinese HIV-1-Infected Patients},
  author={Hua-ying Zhou and Yu-huang Zheng and Yan He and Zi Chen and Meng Liu and Wei Yin and Chun Liu},
  journal={Intervirology},
  year={2010},
  volume={53},
  pages={240 - 246}
}
Objective: To evaluate the long-term efficacy and tolerability of nevirapine (NVP)-based regimens in the treatment of human immunodeficiency virus (HIV)-infected Chinese patients in routine clinical practice. Methods: From October 2002 to May 2004, 57 HIV-1-infected patients commenced antiretroviral therapy (ART), and were followed up to December 2008. These antiretroviral-naïve patients, who originally received two nucleoside reverse transcriptase inhibitors and NVP, had HIV RNA levels, T… 
View on PubMed
karger.com
13 Citations
Highly Influential Citations
1
Background Citations
5

Tables from this paper

13 Citations

Use of first line antiretroviral therapy from a free ART programme clinic in Pune, India - A preliminary report

The first line treatment was effective in patients attending a free ART roll out national programme clinic in Pune, India and the adherence level influenced immunological and virological outcomes of patients.

Dynamic observation of IL-33 and its receptors in HIV patients who received HAART.

Serum IL-33 and sST2 levels, and CD4+ST2L+ expression in PBMCs are closely associated with HIV-1 infection and immune reconstitution in patients received HAART, and negatively correlated with the peripheral blood CD3+/CD4+ cell count.

Zidovudine- versus Tenofovir-Based Antiretroviral Therapy for the Initial Treatment of HIV Infection in the Ethnic Minority Region of Liangshan Prefecture, Sichuan Province, China

Among Chinese Yi minority HIV-infected participants, TDF-based HAART was superior to ZDV-basedHAART for initial treatment of HIV infection, suggesting TDF/ZDV regimen should be the regimen of choice in China.

The immune pathogenesis of immune reconstitution inflammatory syndrome associated with highly active antiretroviral therapy in AIDS.

An imbalance of Th1/Th2 cytokines, a consistently low CD(+)CD25(+)Fox3(+) percentage, and a high IL-7 level may be crucial in the pathogenesis of IRIS in AIDS patients who had received HAART.

A randomized case-control study of dynamic changes in peripheral blood Th17/Treg cell balance and interleukin-17 levels in highly active antiretroviral-treated HIV type 1/AIDS patients.

HAART can restore the balance of Th17 and Treg cells as well as the IL-17 level, which may gradually rebuild the immune equilibrium in HIV/AIDS patients.

HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury

It is concluded that therapeutic and drug monitoring of ART, using laboratory identification of phenotypic susceptibilities, drug interactions with other medications, drugs interactions with herbal medicines, and alcohol intake might enable a safer use of this medication.

The Prevalence of HIV Drug Resistance among Treatment-failure Individuals and Treatment-naïve Individuals in China: A Meta-analysis.

The epidemics of drug resistance matched current treatment strategies and interventions in China, and the prevalence of HIV drug resistance to NNRTIs and NRTIs among treatment-failure individuals was high.

Prevalence of Dyslipidemia Among Antiretroviral-Naive HIV-Infected Individuals in China

Among antiretroviral-naive HIV-infected Chinese adults, there was a high prevalence of dyslipidemia characterized by high TG and low HDL, which was associated with lower CD4 counts, and these data support the assessment of lipid profiles before and after initiation of antireTroviral therapy regardless of age.

Characteristics of CD8+ T cell subsets in Chinese patients with chronic HIV infection during initial ART

The results display a complete phenotypical picture of CD8+ cell subsets during initial ART and provide insights for understanding of immune status during ART.

Epidemiological distribution and genotype characterization of hepatitis C virus and HIV co‐infection in Wuhan, China, where the prevalence of HIV is low

Exposure to multiple risk factors associated with HCV transmission was common among patients co‐infected with HIV and HCV, and the distribution of HCV subtypes suggests that the city plays a crucial role as a hub ofHCV transmission in China.

21 References

Evaluation of human immunodeficiency virus type 1-infected Chinese patients treated with highly active antiretroviral therapy for two years.

It is concluded that a regimen of NVP with ddI and d4T provided durable suppression of plasma viral load in HIV-infected patients, with significant improvement in the CD4 cell count, and can be well tolerated by patients with HIV-1 infection.

Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.

Long-term HAART allowed for restoration of CD4+ cell counts and control of viral loads in HIV-1-infected children, however, initiating HAART after severe immunosuppression has occurred is detrimental for the restoration of the CD4- cell count.

Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine

Antiretroviral therapy with indinavir, zidovudine, and lamivudine suppressed HIV viremia and produced continued CD4 cell increases in a majority of subjects for 6 years, demonstrating the durable effects of antiret virus therapy.

Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy

Most patients who achieve and maintain viral suppression on HAART continue to experience CD4 T-cell gains through 4 years of therapy, indicating the immune system's capacity forCD4 T lymphocyte restoration is not limited by low pre-therapy CD4 counts.

A one-year clinical trial using didanosine, stavudine and nevirapine for highly active antiretroviral therapy.

The first virological and immunological outcomes in HIV infected Chinese patients treated with a combination of didanosine, stavudine and nevirapine (2 NRTIs+1 NNRTI) for 52 weeks are reported.

Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level

The results question the benefit of very long-term maintenance of HAART in terms of CD4 gain and HIV-1 DNA reduction.

Limited immune restoration after 3 years’ suppression of HIV-1 replication in patients with moderately advanced disease

Immune restoration was incomplete in patients who started HAART with moderately advanced HIV-1 disease and most changes occurred during the first year, suggesting that this degree of suppression of HIV- 1 replication alone will not suffice to restore immune competence.

The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy

The recovery of CD4 T lymphocytes occurs mainly in the first 2 years after the initiation of ART, and is associated with age and the pre-existing degree of HIV-1-related immunodeficiency, suggesting that the long-term exposure to HIV- 1 infection has caused damage to the immune system that is difficult to correct.

Highly Active Antiretroviral Therapy Decreases Mortality and Morbidity in Patients with Advanced HIV Disease

The effect of HAART was studied in a large multicenter trial of blood transfusion in patients with advanced HIV disease who were also anemic, an indicator of poor prognosis, and estimates of the magnitude of the effect ofHAART on mortality and morbidity are less likely to be confounded by changes in patient mix or medical practice compared with previously published studies.

Mortality and progression to AIDS after starting highly active antiretroviral therapy

Survival probabilities were high among HIV-infected patients initiating HAART at an early stage of infection, and the best therapy strategy is therefore to startHAART at this stage of infections, however, deferring HAART in patients with high CD4 cell counts may be clinically more appropriate given toxicity and adherence problems.